[go: up one dir, main page]

WO2003051365A3 - Utilisation de composes de la famille des benzamides comme agent immunosuppresseur - Google Patents

Utilisation de composes de la famille des benzamides comme agent immunosuppresseur Download PDF

Info

Publication number
WO2003051365A3
WO2003051365A3 PCT/FR2002/004415 FR0204415W WO03051365A3 WO 2003051365 A3 WO2003051365 A3 WO 2003051365A3 FR 0204415 W FR0204415 W FR 0204415W WO 03051365 A3 WO03051365 A3 WO 03051365A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunosuppressant
compounds
benzamide
family
benzamide family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/004415
Other languages
English (en)
Other versions
WO2003051365A9 (fr
WO2003051365A2 (fr
Inventor
Francois Lang
Delphine Carbonnelle
Jean-Yves Petit
Jean-Michel Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Nantes
Original Assignee
Universite de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes filed Critical Universite de Nantes
Priority to AU2002364456A priority Critical patent/AU2002364456A1/en
Publication of WO2003051365A2 publication Critical patent/WO2003051365A2/fr
Publication of WO2003051365A3 publication Critical patent/WO2003051365A3/fr
Publication of WO2003051365A9 publication Critical patent/WO2003051365A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne l’utilisation d’un composé de Formule générale (I) pour l’obtention d’un agent immunosuppresseur ciblant les cellules présentatrices d’antigène en inhibant leur action sur les lymphocytes T et plus particulièrement dans le traitement du rejet de greffe ou de la réaction du greffon à l’hôte, le lupus érythémateux disséminé, la sclérodermie, le diabète juvénile insulinodépendant, la polyarthrite rhumatoïde, la maladie de Crohn, le syndrome de Goodpasture, la myasthénie, le rhumatisme articulaire aigu, l’uvéite, la pelade, le vitiligo, l’hépatite auto-immune, la lèpre, l’endocardite aigue, l’hépatite, la tuberculose, la lèpre interpolaire et mycose profonde.
PCT/FR2002/004415 2001-12-19 2002-12-18 Utilisation de composes de la famille des benzamides comme agent immunosuppresseur Ceased WO2003051365A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364456A AU2002364456A1 (en) 2001-12-19 2002-12-18 Use of compounds of the benzamide family as immunosuppressant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/16443 2001-12-19
FR0116443A FR2833494B1 (fr) 2001-12-19 2001-12-19 Utilisation de composes de la famille des benzamides comme agent immunosuppresseur

Publications (3)

Publication Number Publication Date
WO2003051365A2 WO2003051365A2 (fr) 2003-06-26
WO2003051365A3 true WO2003051365A3 (fr) 2004-03-04
WO2003051365A9 WO2003051365A9 (fr) 2004-05-06

Family

ID=8870680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/004415 Ceased WO2003051365A2 (fr) 2001-12-19 2002-12-18 Utilisation de composes de la famille des benzamides comme agent immunosuppresseur

Country Status (3)

Country Link
AU (1) AU2002364456A1 (fr)
FR (1) FR2833494B1 (fr)
WO (1) WO2003051365A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254322A1 (fr) * 1986-07-25 1988-01-27 Nisshin Flour Milling Co., Ltd. Dérivés de benzimidazole
EP0632026A1 (fr) * 1993-06-30 1995-01-04 Adir Et Compagnie Nouveaux dérivés d'alpha amino acides leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0684241A1 (fr) * 1994-05-27 1995-11-29 Adir Et Compagnie N-pyridyl carboxamides et dérivés, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254322A1 (fr) * 1986-07-25 1988-01-27 Nisshin Flour Milling Co., Ltd. Dérivés de benzimidazole
EP0632026A1 (fr) * 1993-06-30 1995-01-04 Adir Et Compagnie Nouveaux dérivés d'alpha amino acides leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0684241A1 (fr) * 1994-05-27 1995-11-29 Adir Et Compagnie N-pyridyl carboxamides et dérivés, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOBIN-DUBIGEON, CHRISTINE ET AL: "Effects of tumour necrosis factor-.alpha. synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis", EUROPEAN JOURNAL OF PHARMACOLOGY (2001), 431(1), 103-110, XP001086487 *
DEBORD, J. ET AL: "Cholinesterase inhibition by derivatives of 2-amino-4,6- dimethylpyridine", JOURNAL OF ENZYME INHIBITION (1997), 12(1), 13-26, XP008006792 *
DUFLOS M ET AL: "6-Amino-2,4-lutidine carboxamides: alpha-aminoamide derivatives as systemic and topical inflammation inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 33, no. 7-8, 8 July 1998 (1998-07-08), pages 635 - 645, XP004140557, ISSN: 0223-5234 *
LE PAPE, PATRICE ET AL: "Activity of N-lutidinylarylcarboxamides against Leishmania donovani and L. braziliensis", ACTA PARASITOLOGICA (1999), 44(3), 156-159, XP008006794 *
ROBERT J ET AL: "Non-carboxylic antiinflammatory compounds. III. N-(4,6-Dimethylpyridin-2-yl)arylcarboxamides and arylthiocarboxamides acting as brain edema inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 30, no. 12, 1995, pages 915 - 924, XP004040220, ISSN: 0223-5234 *
ROBERT, JEAN MICHEL ET AL: "Synthesis and anti-inflammatory activity of polyazaheterocyclic derivatives of 6-amino-2,4-lutidine and their precursors", ARZNEIMITTEL-FORSCHUNG (1997), 47(5), 635-642, XP001074265 *
VERNHET, LAURENT ET AL: "An anti-inflammatory benzamide derivative inhibits the protein kinase C (PKC)-dependent pathway of Erk2 phosphorylation in murine macrophages", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (1997), 283(1), 358-365, XP008006793 *

Also Published As

Publication number Publication date
AU2002364456A8 (en) 2003-06-30
FR2833494A1 (fr) 2003-06-20
WO2003051365A9 (fr) 2004-05-06
AU2002364456A1 (en) 2003-06-30
WO2003051365A2 (fr) 2003-06-26
FR2833494B1 (fr) 2006-12-15

Similar Documents

Publication Publication Date Title
WO2004035569A3 (fr) Nouveaux composes antibacteriens
WO2005049616A8 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines a effet inhibiteur par rapport a la pde-5
TW200738672A (en) Intermediated for the preparation of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
WO2001017972A3 (fr) Nouveaux herbicides
WO2004018449A8 (fr) Derives de piperidine utilises comme inhibiteurs de la phospodiesterase-4 (pde4)
HK1053831A1 (zh) 作为治疗药物的激酶抑制剂
WO2002004444A3 (fr) Carboxamides heterocycliques utilises comme agents antiviraux
WO2004018451A8 (fr) Derives de pyridazinone utilises comme inhibiteurs de pde4
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
NZ513164A (en) Substituted porphyrins
WO2002004422A3 (fr) Carboxamides heterocycliques comme agents antiviraux
WO2003006425A3 (fr) Nouveaux composes convenant comme anti-inflammatoires, immuno-modulateurs et anti-proliferants
IL158485A (en) Spiropyrazole compounds
PL369530A1 (en) Chemical compounds
WO2002062792A1 (fr) Inhibiteur de jnk
WO2004018457A8 (fr) Piperidine-phthalazones a substitution pyrrolidinedione utilises comme inhibiteurs de la phosphodiesterase-4 (pde4)
EP1704856A4 (fr) Inhibiteur de proteines de la famille hsp90
WO2001090071A3 (fr) Iminoazines substituees
AU7824900A (en) Compounds and methods for inhibiting mrp1
WO2002085291A3 (fr) Analogues de la nociceptine
WO2004030664A3 (fr) Nouveaux composes pouvant inhiber une proliferation de cellules non desiree et leur utilisation
WO2004048380A8 (fr) Procede de synthese de ganciclovir
WO2005061496A8 (fr) Derives aminopyridines en tant qu'inhibiteurs de la no-synthase inductible-
WO2005097799A8 (fr) Pyrazolo`4,3[4,3-d]pyrimidines
MY129094A (en) Condensed polycyclic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: TRANSLATION OF TEXT OF INTERNATIONAL SEARCH REPORT ADDED (2 PAGES)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP